Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT05216666
Recruiting Not applicable

The Role of Surgical Approach on Residual Limping After Total Hip Arthroplasty

NCT05216666 · tracked via the Priya Life Science Sweden tracker
Sponsor
Sahlgrenska University Hospital
Phase
Not applicable
Started
2022-05-11
Last updated
2025-04-09

Condition(s) studied

Hip OsteoarthritisMuscle WeaknessMuscle AtrophyMuscle InjuryArthroplasty Complications

Investigational drug(s) / intervention(s)

Lateral approachPosterior approach

Lateral approach: Total hip arthroplasty performed through a lateral surgical approach (Gammer)

Posterior approach: Total hip arthroplasty performed through a posterior surgical approach (Moore)

Study summary

Residual limping after total hip arthroplasty is empirically associated with the use of lateral approach but has been reported in litterature even with the use of posterior approach. The purpose of this clinical trial is to compare the risk of residual limping one year after total hip arthropasty between lateral and posterior approach.

Eligibility

Sex
ALL
Min age
40 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Primary unilateral osteoarthritis of the hip scheduled for total hip arthroplasty. * Ability to understand and write swedish. Exclusion Criteria: * Impaired funktion of the contralateral hip or knees causing limping. * Neuromuscular diseases * Postoperative leg length discrepancy excceding 1 cm * Postoperative discrepancy in femoral offset exceeding 25% of the femoral offset of the contralateral hip.

Primary outcome measure(s)

  • Trendelenburg sign as binary variable (positive/negative) — At 12 months after intervention
    Trendelenburg sign negative if the pelvis remains horisontal while standing only on the operated leg with both arms in anatomical postion. If the pelvismcannot be kept horisontal and tilts towards the kontralateral hip the Trendelenburgs sign is regarded as positive.

Trial sites (1)

FacilityCityRegionStatus
Sahlgrenska University Hospital Mölndal Sweden Recruiting

More Sahlgrenska University Hospital trials in Sweden

Reperfusion Treatment in Acute Pulmonary Embolism Recruiting
Achilles Tendon for the Treatment of Gluteus Medius Insufficiency Recruiting
Watch and Wait as Treatment for Patients With Rectal Cancer Recruiting
CBT Treatment for Internet Gaming Disorder Starting soon
Acute Achilles Tendon Rupture - Choice of Treatment Based on Ultrasound Findings Active, not recruiting

Other trials for the same condition

Achilles Tendon for the Treatment of Gluteus Medius Insufficiency Recruiting
MOVE-HIP: Ceramic Hip Resurfacing Versus Total Hip Arthroplasty Using Activity Monitoring Recruiting
PT-led Triage for Patients With Hip o Knee Osteoarthritis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05216666 on ClinicalTrials.gov ↗ ← All trials in Sweden